Recruiting soon

Collagen Peptide Supplementation for Wound Healing After Knee Replacement Surgery

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to evaluate whether taking collagen peptide supplements before knee replacement surgery affects mRNA levels in the anterior cruciate ligament.

What is being tested

SOLUGEL

+ Placebo

Dietary Supplement
Who is being recruted

Arthritis+3

+ Joint Diseases

+ Musculoskeletal Diseases

From 50 to 75 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: February 2026
See protocol details

Summary

Principal SponsorUniversity of Arkansas
Study ContactShiloah Kviatkovsky
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2026

Actual date on which the first participant was enrolled.

This study aims to investigate whether taking collagen peptide supplements can help with tissue healing, functional outcomes, and wound healing for people undergoing total knee replacement surgery. The focus is on individuals who are planning to have this surgery, as the researchers want to see if these supplements can improve recovery and overall outcomes. This is important because knee replacement surgery can have a significant impact on daily life, and finding ways to enhance recovery could greatly benefit those undergoing the procedure. During the study, participants will either take a collagen peptide supplement or a placebo over 24 weeks. Before and after surgery, various tests and assessments will be done, including checking knee function, mood, physical activity, and pain levels. Blood and tissue samples will be collected during surgery to monitor changes at a molecular level. Physical therapy is also part of the recovery process. The results are measured through a series of physical and functional tests, ensuring a comprehensive look at how the supplements might aid recovery. Participants will have both in-person and virtual check-ins to monitor progress and adherence to the study plan.

Official TitleEffects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)
Principal SponsorUniversity of Arkansas
Study ContactShiloah Kviatkovsky
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

44 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 50 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

ArthritisJoint DiseasesMusculoskeletal DiseasesOsteoarthritisRheumatic DiseasesOsteoarthritis, Knee

Criteria

Inclusion Criteria: * Males and Females, 50 to 75 years old * With a body mass index of 20.0 to 39.9 kg/m2 * Diagnosed with primary osteoarthritis * Scheduled for a TKA at UAMS (two months prior to surgery) at UAMS * Live near Little Rock and scheduled to attend physical therapy in Little Rock * COVID-19 negative and/or asymptomatic. Exclusion Criteria: * Previously sustained serious knee injury or surgery to ACL in TKA knee * Females not postmenopausal * Having undergone hormone replacement therapy in the last 12 months. * Active diagnosis of blood borne infectious disease

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
10 grams per day for 24 weeks

Group II

Placebo
10 grams per day maltodextrin for 24 weeks

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
Recruiting soonNo study centers